NMRA is trading 6% up today at $1.60 in pre-market, seeing a modest bounce following a significant collapse earlier this month.
- The stock's recent decline was driven by failed Phase 3 clinical trials for its depression treatment and subsequent workforce reductions.
- With no fresh company-specific headlines on June 26, 2026, the current move likely reflects bargain hunting and technical repricing rather than a new fundamental catalyst.